A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
Year of publication: |
2001
|
---|---|
Authors: | Gabriel, Sherine E. ; Coyle, Douglas ; Moreland, Larry W. |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 19.2001, 7, p. 715-728
|
Publisher: |
Springer Healthcare | Adis |
Subject: | Antimalarials | Antirheumatics | Auranofin | Azathioprine | Cost analysis | Cyclophosphamide | Cyclosporin | Disease modifying antirheumatics | Etanercept | Gold | Infliximab | Leflunomide | Methotrexate | Penicillamine | Pharmacoeconomics | Rheumatoid arthritis | Sulfasalazine |
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
-
Maetzel, Andreas, (2002)
-
A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
Nuijten, Mark J.C., (2001)
-
Management of Rheumatoid Arthritis: Defining the Role of Etanercept
Keating, Gillian M., (2002)
- More ...
-
Increasing the impact of economic evaluations on health-care decision-making
Coyle, Douglas, (1993)
-
Coyle, Douglas, (2003)
-
Medu, Olanrewaju, (2021)
- More ...